CUREXO dashes into overseas markets with last year’s results, achieving best quarterly performance ever
Date : 2021-02-10
Curexo, a medical robot company, said it recorded its highest quarterly performance thanks to increased sales of medical robots in the fourth quarter of 2020.
According to the company, sales in the fourth quarter were 12.7 billion KRW (YoY +39%, QoQ +41.7%), operating profit was 14.8 billion (YoY surplus conversion, QoQ +250.1%), and net profit was 1.66 billion (YoY surplus conversion, QoQ +165%) respectively. The annual sales grew 14.2 percent year-on-year to 392.8 billion, operating profit reached 7.3 billion, and net profit reached 640 billion KRW, respectively.
Curexo succeeded in expanding sales and making a surplus by supplying its medical robots to various internal and external medical sites last year.
Specifically, last year's results included a total of 18 units, including eight artificial joint surgery robots, "CUVIS-joint," three spinal surgical robots, "CUVIS-spine," and five walking rehabilitation robots, "Morning Walk," to the domestic and overseas medical markets. As a result, Curexo has established itself as a leading medical robot company in Korea and has secured both growth and profitability.
The company's CEO, Lee Jae-jun, said, "As a representative of the company, I am grateful that we were able to supply medical robots to the domestic and overseas medical markets with the dedication and efforts of executives and employees even amidst COVID-19."
"In the second quarter of this year, we are aiming to obtain domestic and overseas licenses," he added. "We will not stop at last year’s success but do our best to advance into developed markets such as the U.S. and Europe, the cores of global medical robot markets, establishing the status of K-medical robots in the global medical robot market by signing strategic partnerships, promoting joint projects, and building brand awareness and expanding supplies."
https://www.k-health.com/news/articleView.html?idxno=52292
According to the company, sales in the fourth quarter were 12.7 billion KRW (YoY +39%, QoQ +41.7%), operating profit was 14.8 billion (YoY surplus conversion, QoQ +250.1%), and net profit was 1.66 billion (YoY surplus conversion, QoQ +165%) respectively. The annual sales grew 14.2 percent year-on-year to 392.8 billion, operating profit reached 7.3 billion, and net profit reached 640 billion KRW, respectively.
Curexo succeeded in expanding sales and making a surplus by supplying its medical robots to various internal and external medical sites last year.
Specifically, last year's results included a total of 18 units, including eight artificial joint surgery robots, "CUVIS-joint," three spinal surgical robots, "CUVIS-spine," and five walking rehabilitation robots, "Morning Walk," to the domestic and overseas medical markets. As a result, Curexo has established itself as a leading medical robot company in Korea and has secured both growth and profitability.
The company's CEO, Lee Jae-jun, said, "As a representative of the company, I am grateful that we were able to supply medical robots to the domestic and overseas medical markets with the dedication and efforts of executives and employees even amidst COVID-19."
"In the second quarter of this year, we are aiming to obtain domestic and overseas licenses," he added. "We will not stop at last year’s success but do our best to advance into developed markets such as the U.S. and Europe, the cores of global medical robot markets, establishing the status of K-medical robots in the global medical robot market by signing strategic partnerships, promoting joint projects, and building brand awareness and expanding supplies."
https://www.k-health.com/news/articleView.html?idxno=52292
